



The Effectiveness of Procedures to Remove or Occlude the Left Atrial Appendage: A Systematic Review of the Evidence

October 2015

Prepared for:

Department of Veterans Affairs
Veterans Health Administration
Quality Enhancement Research Initiative
Health Services Research & Development Service
Washington, DC 20420

Prepared by:

Evidence-based Synthesis Program (ESP)
Portland VA Medical Center
Portland, OR
Devan Kansagara, MD, Director

Investigators:

Principal Investigator:
North Noelck, MD

Co-Investigators:

Joel Papak, MD
Michele Freeman, MPH
Robin Paynter, MLIS
Allison Low, BA
Makalapua Motu'apuaka, BA
Karli Kondo, PhD
Devan Kansagara, MD



PREFACE

The VA Evidence-based Synthesis Program (ESP) was established in 2007 to provide timely and accurate syntheses of targeted healthcare topics of particular importance to clinicians, managers, and policymakers as they work to improve the health and healthcare of Veterans. QUERI provides funding for four ESP Centers, and each Center has an active University affiliation. Center Directors are recognized leaders in the field of evidence synthesis with close ties to the AHRQ Evidence-based Practice Centers. The ESP is governed by a Steering Committee comprised of participants from VHA Policy, Program, and Operations Offices, VISN leadership, field-based investigators, and others as designated appropriate by QUERI/HSR&D.

The ESP Centers generate evidence syntheses on important clinical practice topics. These reports help:

- Develop clinical policies informed by evidence;
- Implement effective services to improve patient outcomes and to support VA clinical practice guidelines and performance measures; and
- Set the direction for future research to address gaps in clinical knowledge.

The ESP disseminates these reports throughout VA and in the published literature; some evidence syntheses have informed the clinical guidelines of large professional organizations.

The ESP Coordinating Center (ESP CC), located in Portland, Oregon, was created in 2009 to expand the capacity of QUERI/HSR&D and is charged with oversight of national ESP program operations, program development and evaluation, and dissemination efforts. The ESP CC establishes standard operating procedures for the production of evidence synthesis reports; facilitates a national topic nomination, prioritization, and selection process; manages the research portfolio of each Center; facilitates editorial review processes; ensures methodological consistency and quality of products; produces “rapid response evidence briefs” at the request of VHA senior leadership; collaborates with HSR&D Center for Information Dissemination and Education Resources (CIDER) to develop a national dissemination strategy for all ESP products; and interfaces with stakeholders to effectively engage the program.

Comments on this evidence report are welcome and can be sent to Nicole Floyd, ESP CC Program Manager, at Nicole.Floyd@va.gov.

Recommended citation: Noelck N, Papak J, Freeman M, Paynter R, Low A, Motu’apuaka M, Kondo K, Kansagara D. The Effectiveness of Procedures to Remove or Occlude the Left Atrial Appendage: A Systematic Review of the Evidence. VA ESP Project #05-225; 2015.

This report is based on research conducted by the Evidence-based Synthesis Program (ESP) Center located at the **Portland VA Health Care System, Portland, OR**, funded by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research Initiative. The findings and conclusions in this document are those of the author(s) who are responsible for its contents; the findings and conclusions do not necessarily represent the views of the Department of Veterans Affairs or the United States government. Therefore, no statement in this article should be construed as an official position of the Department of Veterans Affairs. No investigators have any affiliations or financial involvement (eg, employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties) that conflict with material presented in the report.

TABLE OF CONTENTS

EXECUTIVE SUMMARY	1
Introduction.....	1
Methods.....	1
Data Sources and Searches	1
Study Selection	2
Data Abstraction and Quality Assessment.....	2
Data Synthesis and Analysis.....	2
Peer review.....	2
Summary of Findings.....	2
Summary of evidence	2
Research Gaps/Future Research	3
Conclusions.....	3
Table 1. Summary of evidence on the effectiveness of procedures to remove or occlude the left atrial appendage	4
ABBREVIATIONS	5
INTRODUCTION	6
METHODS	7
Topic Development.....	7
Search Strategy	7
Study Selection	8
Data Abstraction	11
Quality Assessment.....	11
Data Synthesis.....	11
Rating the Body of Evidence	11
Peer Review	11
RESULTS	12
Literature Flow.....	12
Figure 1. Literature flow diagram.....	13
Percutaneous LAA interventions	14
KQ1: What is the effectiveness of LAA exclusion interventions compared with usual care?	14
KQ2: What are the harms associated with LAA exclusion?.....	15
KQ3a: How do the benefits of LAA exclusion vary in different subgroups?	15
KQ3b: How do the harms of LAA exclusion vary in different subgroups?	16

KQ4: What are the comparative effects of different techniques on health outcomes and rates of procedural success? 16

Surgical LAA interventions 22

 KQ1: What is the effectiveness of LAA exclusion interventions compared with usual care? 22

 KQ2: What are the harms associated with LAA exclusion?..... 23

 KQ3: How do the benefits and harms of LAA exclusion vary in different subgroups?..... 23

 KQ4: What are the comparative effects of different techniques on health outcomes and rates of procedural success? 23

SUMMARY AND DISCUSSION..... 28

 Percutaneous LAA exclusion..... 28

 Surgical LAA exclusion..... 30

 Limitations 32

 Research Gaps/Future Research 32

 Conclusions..... 33

REFERENCES..... 34

TABLES AND FIGURES

 Table 1. PICOTS and Key Questions for Percutaneous LAA Interventions 9

 Table 2. PICOTS and Key Questions for Surgical LAA Interventions 10

 Figure 1. Literature flow diagram..... 13

 Table 3. Health outcomes, adverse effects, and procedural success in trials comparing percutaneous LAAO to warfarin therapy..... 17

 Table 4. Procedural success, harms, and long-term stroke risk in registry studies of percutaneous LAA exclusion..... 18

 Table 5. Characteristics and findings of trials of cardiac surgery with vs without concomitant LAA occlusion or removal..... 25

 Table 6. Characteristics and findings of cohort studies of cardiac surgery with vs without concomitant LAA occlusion or removal..... 26

 Table 7. Summary of the evidence on percutaneous and surgical interventions to occlude or remove the LAA 31

 Table 8. Ongoing studies of percutaneous and surgical LAA interventions 32

APPENDIX A. SEARCH STRATEGIES..... 38

APPENDIX B. STUDY SELECTION 41

APPENDIX C. QUALITY ASSESSMENT 42

 Table 9. Quality assessment of trials of percutaneous LAA interventions..... 42

Table 10. Quality assessment of trials of surgical LAA interventions 43

Table 11. Quality assessment of cohort studies surgical LAA interventions 45

APPENDIX D. LAA DEVICE MANUFACTURERS 47

APPENDIX E. PEER REVIEWER COMMENTS AND AUTHOR RESPONSES 48



EVIDENCE REPORT

INTRODUCTION

Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting between 2.7 and 6.1 million people in the United States.¹ The prevalence of AF increases with age and is often associated with structural heart disease and co-morbidities that are common in the Veteran population. Complications related to AF can be classified as hemodynamic or thromboembolic.

Cardioembolic strokes account for 14-36% of all ischemic strokes, and AF is the most important cause of cardioembolic stroke. In general, the risk of stroke in patients with non-valvular AF is 2 to 7 times higher than patients without AF.² Antithrombotic therapy with aspirin, warfarin, or one of several newer oral anticoagulants have been the mainstay of stroke prevention in atrial fibrillation, but may be cumbersome and are associated with an increased risk of bleeding.

The mechanism of thrombosis formation is stasis of blood in the left atrium and it is currently believed that a high percentage of thromboemboli develop in the left atrial appendage (LAA).^{3,4} Thus, various procedures have been developed that attempt to isolate the LAA from circulating blood flow in an effort to reduce the risk of thromboembolic stroke. These methods include surgical occlusion or removal of the LAA, and percutaneous, catheter-based approaches to occlude the LAA. The LAA is, however, only one potential source of strokes and patients at the highest risk of stroke related to AF frequently have associated risk factors for stroke that are independent of AF. These risk factors – including hypertension, diabetes, and advanced age – increase a patient’s likelihood of an ischemic stroke secondary to atherosclerotic aortic or carotid disease which would not be addressed by exclusion or removal of the LAA.

Prior to 2002, surgery was the only option for exclusion of the LAA. This could be done in conjunction with surgery being performed for other reasons, such as coronary artery bypass grafting (CABG) or valve replacement in patients who also have or are at risk for AF, or as part of a mini-thoracotomy typically in association with a maze procedure. Surgical approaches to LAA exclusion include simple suture ligation, oversewing the base without excision, excising the appendage and oversewing the base, or surgical stapling and excision.¹

More recently, a number of devices designed to occlude the LAA percutaneously have been developed. The devices currently in use include the Percutaneous Left Atrial Appendage Transcatheter Occlusion (PLAATO) device (Appriva Medical, Plymouth, Minnesota), the Amplatzer device (AGA Medical Corporation/St. Jude Medical, Golden Valley, Minnesota), the Watchman device (Boston Scientific, Natick, Massachusetts), and the LARIAT suture delivery device (SentreHeart, Redwood City, California). Given the high prevalence of atrial fibrillation in the general and Veteran population, along with the potential risks and inconvenience of long-term oral anticoagulant therapy, there is a growing interest in LAA occlusion or removal as an alternative stroke risk reduction strategy. The purpose of this report is to systematically review the literature to better understand the balance of benefits and harms of surgical or percutaneous LAA occlusion or removal. We use the general term LAA exclusion throughout the report to refer to either removal or isolation of the LAA, except where otherwise specified.

METHODS

TOPIC DEVELOPMENT

The topic of this review was nominated by Dr. Alaa Shalaby, a member of the VHA Cardiology Field Advisory Committee and Director of Cardiac Electrophysiology at the VA Pittsburgh Healthcare System. Dr. William Gunnar, National Director of Surgery for the Veterans Health Administration, also served as an operational partner.

The research questions for this systematic review were developed after a topic refinement process that included a preliminary review of published peer-reviewed literature, consultation with internal partners and investigators, and consultation with content experts and key stakeholders. The key questions (KQs) that this review sought to address are as follows:

KQ1. What is the effectiveness of surgical or percutaneous LAA exclusion compared with usual care?

KQ2. What are the harms associated with surgical or percutaneous LAA exclusion?

KQ3. How do the benefits and harms of LAA exclusion vary in different subgroups?

KQ4. What are the comparative effects of different techniques (surgical and percutaneous) of LAA exclusion on rates of procedural success?

A protocol describing the review plan was posted to a publicly accessible website before the study was initiated.⁵

SEARCH STRATEGY

Search strategy was developed in consultation with a research librarian, and was peer reviewed by a second research librarian using the instrument for Peer Review of Search Strategies (PRESS).^{6,7} To identify relevant articles, we searched Ovid MEDLINE[®], Embase[®], the Cochrane databases, and the FDA Devices database from database inception through January 7, 2015. We further reviewed the bibliographies of systematic reviews and other relevant articles for additional studies. To identify in-progress or unpublished studies, we searched ClinicalTrials.gov, the Conference Abstracts database, the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP), and contacted device manufacturers to inquire for unpublished trial data.

Using pre-specified inclusion/exclusion criteria, we reviewed titles and abstracts for relevance to the key questions. At the full-text screening stage, 2 independent reviewers concurred on final inclusion/exclusion decisions, with input from a third investigator when needed to resolve questions and reach consensus. Articles meeting eligibility criteria were included for data abstraction.

STUDY SELECTION

The criteria for patient population, intervention, comparator, outcome, timing parameters, and study designs (PICOTS) that apply to each key question are specified in Table 1 (percutaneous procedures) and Table 2 (surgical procedures). Given the availability of larger-scale trials of percutaneous procedures, along with recent systematic reviews of percutaneous approaches to LAA exclusion, we only included controlled clinical trials to assess the effectiveness of percutaneous LAA exclusion procedures. On the other hand, we included cohort studies with or without a control population to examine harms of percutaneous interventions.⁸ After an initial survey of the literature, we found there were a number of larger cohort studies providing harms data and therefore set a sample size cut-off of 50 or more patients for inclusion.

We included cohort studies in addition to controlled clinical trials for all key questions examining benefits and harms of surgical procedures.⁸ However, given that the LAA exclusion procedures were usually done in the context of heart surgery and that the harms related to LAA exclusion would be difficult to distinguish from those of the heart surgery itself, we only included cohort studies with a control population of patients who received heart surgery but no LAA exclusion.

Table 1. PICOTS and Key Questions for Percutaneous LAA Interventions

Key Question	KQ1. What is the effectiveness of LAA exclusion interventions compared with usual care?	KQ2. What are the harms associated with LAA exclusion?	KQ3a. How do the benefits LAA exclusion vary in different subgroups? KQ3b. How do the harms of LAA exclusion vary in different subgroups?	KQ4. What are the comparative effects of different techniques on rates of procedural success?
Population	Patients with atrial fibrillation who are eligible for percutaneous LAA exclusion			
Intervention	<ul style="list-style-type: none"> • AMPLATZER™ Cardiac Plug (company: AGA Medical, Corp., North Plymouth, MN, USA) • WATCHMAN® Left Atrial Appendage Closure Technology/Device/System (company: Atritech, Inc., North Plymouth, MN, USA) • PLAATO™ Percutaneous Left Atrial Appendage Transcatheter Occlusion (company: Appriva Medical, Inc., Sunnyvale, CA) • Coherex WaveCrest™ LAA Occluder System (company: Coherex Medical, Inc., Salt Lake City, Utah, USA) • LARIAT suture delivery device (SentreHeart, Redwood City, California) • Lifetech LAmbré™ Left Atrial Appendage Occluder <i>Device</i> (Lifetech Scientific Co., Ltd) Nanshan District, Shenzhen, PEOPLE’S REPUBLIC OF CHINA 			
Comparator	Usual care without LAA exclusion			Compares percutaneous intervention to another LAA closure technique (surgical, thoracoscopic, or percutaneous)
Outcomes	<p>Primary outcomes:</p> <ul style="list-style-type: none"> § Stroke § Mortality § Cardiovascular morbidity § Other reported health outcomes 	<ul style="list-style-type: none"> § Harms other than primary outcomes for KQ1 § length of stay (hospital and ICU) § bleeding § infection § need for surgical intervention 	<ul style="list-style-type: none"> § Primary outcomes listed in KQ1 § Other reported benefits and harms § Rates of bleeding. 	<p><u>Procedural outcome:</u> Successful closure/LAA removal, assessed by methods such as transesophageal echocardiogram; CT; MRI.</p> <p><u>Health outcomes:</u> Same as those listed for KQ1.</p>
Timing	Short- and long-term outcomes			
Study design	<p><u>Include:</u> Systematic reviews, meta-analyses, or randomized controlled trials. For KQ2 and KQ3b, we will additionally include cohort and trial extension studies that report data on adverse events.</p> <p><u>Exclude:</u> Non-systematic or narrative reviews, non-randomized trials, opinions, case studies, case series, and quasi-experimental studies.</p>			

Table 2. PICOTS and Key Questions for Surgical LAA Interventions

Key Question	KQ1. What is the effectiveness of LAA exclusion interventions compared with usual care?	KQ2. What are the harms associated with LAA exclusion?	KQ3. How do the benefits and harms of LAA exclusion vary in different subgroups?	KQ4. What are the comparative effects of different techniques on health outcomes and rates of procedural success?
Population	Patients undergoing cardiac surgery: coronary bypass surgery; valvular surgery; or both bypass and valve surgery.	Patients undergoing surgical LAA occlusion/removal in combination with surgery for atrial fibrillation (<i>ie</i> , MAZE).	Patients undergoing surgical LAA exclusion.	Non-selected population of patients with atrial fibrillation
Intervention	<ul style="list-style-type: none"> • LAA occlusion/removal techniques that involve major surgery (sternotomy or thoracotomy), <i>eg</i>: <ul style="list-style-type: none"> § specific devices such as AtriClip, or § techniques such as stapling or suturing • LAA occlusion/removal via thoracoscopic surgery • Minimally invasive Maze procedures if there are data about the incremental effects of concomitant LAA exclusion. 			
Comparator	Cardiac surgery without LAA removal or occlusion.	Surgery for atrial fibrillation without LAA removal.	Non-surgical/usual care for thromboembolic stroke prevention, such as aspirin for patients with CHADS2 of 0 or 1, and antithrombotic therapy with warfarin or a NOAC (apixiban, dabigatran, rivaroxaban) for CHADS2 of ≥ 1 .	Compares surgical intervention to another LAA closure technique (surgical, thoracoscopic, or percutaneous)
Outcomes	<p>Primary outcomes:</p> <ul style="list-style-type: none"> § Stroke § Mortality § Cardiovascular morbidity § Other reported health outcomes 	<ul style="list-style-type: none"> § Harms other than primary outcomes for KQ1 § length of stay (hospital and ICU) § time on bypass § bleeding § ventilator days § infection 	<ul style="list-style-type: none"> § Primary outcomes listed in KQ1 § Other reported benefits and harms § Rates of bleeding. 	<p><u>Procedural outcome:</u> Successful closure/LAA removal, assessed by methods such as transesophageal echocardiogram; CT; MRI.</p> <p><u>Health outcomes:</u> Same as those listed for KQ1.</p>
Timing	Short- and long-term outcomes			
Study design	<p><u>Include:</u> Systematic reviews, meta-analyses, controlled clinical trials (randomized or non-randomized), and methodologically rigorous observational studies (case control/cohort studies) that adjust for important confounders, <i>eg</i>, propensity score matching</p> <p><u>Exclude:</u> Non-systematic or narrative reviews, opinions, case studies, case series, and quasi-experimental studies.</p>			

DATA ABSTRACTION

One investigator (among NN, JP, and MF) abstracted data from published reports into a customized database, and entries were confirmed by a second reviewer. From each study, we abstracted study design, objectives, setting, population characteristics (including sex, age, race/ethnicity), subject eligibility and exclusion criteria, number of subjects, years of enrollment, duration of follow-up, the study and comparator interventions, important co-interventions, health outcomes, and adverse events. A second author reviewed the entries for accuracy.

QUALITY ASSESSMENT

Two reviewers (among NN, DK, JP, and MF) independently assessed the quality of each trial using a tool developed by the Cochrane Collaboration (Appendix C).⁹ We assigned each trial an overall summary assessment of low, high, or unclear risk of bias.

For evaluating cohort studies of surgical LAA interventions, we used the Newcastle-Ottawa criteria to assess methodological rigor and consider potential sources of bias.¹⁰ We did not assign overall quality ratings, however, as validated criteria for ranking observational studies are not currently available.

DATA SYNTHESIS

We qualitatively synthesized the evidence on the benefits and harms of LAA exclusion. Clinical heterogeneity and the small number of trials precluded the possibility of combining the findings in meta-analysis.

RATING THE BODY OF EVIDENCE

We assessed the overall quality of evidence for each outcome using a method developed by the Agency for Healthcare Research and Quality (AHRQ).¹¹ We considered the consistency, coherence, and applicability of the body of evidence, as well as the internal validity of individual studies, to classify the strength of evidence for each outcome as follows:

High = Further research is very unlikely to change our confidence on the estimate of effect.

Moderate = Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low = Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Insufficient = Any estimate of effect is very uncertain.

PEER REVIEW

A draft version of this report was reviewed by 5 individuals with technical expertise and clinical leadership. Their comments and our responses are presented in Appendix E.


RESULTS

We reviewed 2,566 titles and abstracts, including 2,469 from the electronic search and an additional 98 from reviewing reference lists and performing manual searches for recently published and unpublished or ongoing studies. After applying inclusion/exclusion criteria at the abstract level, we reviewed 207 full-text articles from which we found 20 primary studies that met our inclusion criteria. We also identified 5 systematic reviews of the effectiveness of percutaneous LAA devices. We contacted 7 device companies to request information about unpublished studies but received no response (Appendix D).

LITERATURE FLOW

The diagram on the following page shows the yield of citations from database searches and other sources, the numbers of excluded abstracts and full-text articles, and the final yield of included studies (Figure 1).

Figure 1. Literature flow diagram



PERCUTANEOUS LAA INTERVENTIONS

KQ1: What is the effectiveness of LAA exclusion interventions compared with usual care?

We found 2 randomized controlled trials (RCTs) with low risk of bias, both of which compared the Watchman(R) Left Atrial Appendage Closure Device (Atritech, Inc., North Plymouth, MN, USA) to medical therapy with warfarin (Table 3). Inclusion into the PROTECT-AF¹²⁻¹⁴ trial required subjects to have non-valvular atrial fibrillation (NVAF) and a CHADS2¹⁵ score of at least 1, while the PREVAIL¹⁶ trial enrolled subjects with higher risk of stroke; patients were excluded from these trials if they had contraindication to warfarin therapy, recent stroke, or a patent foramen ovale/atrial septal defect.

The PROTECT-AF trial included 463 intervention and 244 control patients with non-valvular atrial fibrillation, and excluded patients with low stroke risk (CHADS2 of 0). The device was successfully deployed in 88% (408/463) of patients, though it was not attempted in 14 patients. Successful closure was obtained in 86% (348/401) of patients at 45 days and in 92% (355/385) at 6 months. Warfarin was typically discontinued with complete closure or if residual peri-device flow was less than 5 mm width on surveillance transesophageal echocardiogram (TEE). At 6 months, successful closure was demonstrated in 92% (355/385), although 5.6% (23/408) refused follow-up TEE. Most patients were able to stop warfarin therapy (7.5% (30/401), 3.6% (14/385), and 2.7% (10/370) of subjects in the LAA exclusion group remained on warfarin therapy at 45 days, 6 months, and 2 years respectively.^{13,14} The control arm was within therapeutic international normalized ratio (INR) range 66% of the time.

There was no difference in a composite primary efficacy endpoint including ischemic/hemorrhagic stroke, cardiovascular/unexplained death, and systemic embolism with 3.0 (1.9 to 4.5) events per 100 patient-years in the LAA exclusion group versus 4.9 (2.8 to 7.1) events per 100 patient-years in the warfarin group (rate ratio 0.62, 0.35 to 1.25). Cumulative events at 2.3 years mean follow up (standard deviation 1.1 years, median 2.4, range 0.5 to 9 years) were also similar with 3.0 (2.15 to 4.3) events per year in the LAA exclusion group versus 4.3 (2.6 to 5.9) events per year in the warfarin group. Overall, there was >99.9% posterior probability for non-inferiority for the LAA exclusion group compared to the warfarin treated group.^{13,14} Additionally, there was no statistically significant difference in mortality between the 2 groups.

In a subset of patients in the PROTECT-AF trial, quality of life on some subscales was modestly improved in the intervention group. However, the absolute differences were small and the findings subject to bias given lack of patient blinding and differential rates of follow-up in each group.¹²

The PREVAIL trial enrolled 407 subjects (269 assigned to LAA exclusion and 138 assigned to warfarin therapy) and followed them for an average of 11.8 months (standard deviation 5.8 months, median 12 months, range 0.03 to 25.9 months).¹⁶ Patients were slightly older and had a higher risk of stroke than the population included in the PROTECT-AF trial. Device deployment was successful in 95.1% (252/269) patients. At 6 months, device closure was demonstrated in 98.3% (235/239), though 11.2% (30/269) refused follow-up TEE.

The PREVAIL trial did not meet its target of non-inferiority for overall efficacy, although event rates were low and numerically comparable for both arms. Overall mortality was 2.6% in the LAA exclusion group versus 2.2% in the warfarin group. A composite outcome of death, ischemic/hemorrhagic stroke, or systemic embolism occurred in 5.2% of the LAA exclusion group and 2.9% of the warfarin group. On the other hand, the rate of events adjusted for person-time of observation months was similar: 18 month rate ratio of composite events was 1.07 (credible interval 0.57 to 1.89).¹⁶ The discrepancy in the reported results may be related to a later occurrence of outcomes in the device group.

KQ2: What are the harms associated with LAA exclusion?

We found 2 trials and 11 observational studies reporting harms data (Tables 3 and 4). Serious periprocedural adverse events were reported in 1.6-13.6% of patients. Overall, the rate of periprocedural harms occurring within 7 days of device placement was 6.5% (98/1506). The types of periprocedural events most commonly reported included pericardial effusions with and without associated tamponade, bleeding, device thrombus, and device embolization.

Two trials examined harms associated with placement of the Watchman device.^{13,16} In PROTECT-AF 10.6% (49/463) of patients experienced a safety event with 55.1% (27/49) of those occurring on the day of the procedure. Significant pericardial effusion followed by major bleeding accounted for most of these events. The authors note the rate of pericardial effusion declined with operator experience. In contrast, the safety event rate was much lower (2.2%) in the more recently conducted PREVAIL trial.¹⁶ Adverse event rates were similar in the single center¹⁷⁻²² and the multicenter studies.²³⁻²⁶

We did not find robust comparative effectiveness data to directly assess the relative rates of serious safety events according to the device used. However, there were serious periprocedural events including death or need for emergent surgery reported for all included devices.

Overall, patients had low rates of stroke and bleeding and there were no reported technical device failures over the long term. Data on longer-term safety from the observational studies is limited in part by either high rates of attrition²⁴ or lack of information about the loss to follow-up.^{17,21,22,26,27} Additionally, the duration of follow-up ranged from 6 months to 5 years and there was no clear standard for which events were reported.

KQ3a: How do the benefits of LAA exclusion vary in different subgroups?

The evidence for use of LAA exclusion devices in different subgroups is limited to retrospective analysis of a single randomized controlled trial of the Watchman device. In PROTECT-AF the use of the Watchman appeared equally effective in men and women and was non-inferior to warfarin in patients with CHADS2 score greater than 1, patients who are greater than or equal to 75 years old, patients with normal and reduced left ventricular ejection fraction (LVEF), patients with prior stroke, and in those with higher CHADS2.²⁵ Findings were also consistent in patients with paroxysmal and permanent atrial fibrillation.²⁵ However, the strength of these findings should be considered low because of the post-hoc nature of these analyses and the relatively wide confidence intervals associated with the findings.

KQ3b: How do the harms of LAA exclusion vary in different subgroups?

The PROTECT-AF and PREVAIL trials of the Watchman device did not address harms in different subgroups.^{13,14,16} The observational studies did not directly compare rates of harms across patient subgroups. In these studies, there were a substantial proportion of older patients with higher stroke risk and the rates and types of periprocedural harms were similar across the studies.

While the 2 RCTs excluded patients who were ineligible to receive anticoagulant therapy, 7 of 11 observational studies included patients who were ineligible for long-term oral anticoagulant therapy. In most of these studies, the long-term rates of stroke were low – 2.1% (12/565) over the course of 6-24 months of follow-up.^{17,19,21,24,25} One study of the PLAATO device found a higher incidence of stroke (12.5%) during a follow-up period which lasted up to 5 years,²⁰ though the annual rate of stroke is similar to studies with shorter follow-up periods. Long-term complications were not reported as part of the CAP Registry.^{26,27}

KQ4: What are the comparative effects of different techniques on health outcomes and rates of procedural success?

Given that RCT data is limited to a single device, the Watchman, and a single technique, it is impossible to compare the effectiveness of different techniques. The PREVAIL trial included analysis of the learning curve for implantation of the Watchman by requiring a minimum of 20% of participants from centers that had not previously participated in LAA exclusion trials with this device, as well as a requirement that a minimum of 25% of randomized patients be treated by new operators. The study found an overall implantation success of 95.1%., with no statistically significant difference in successful deployment when comparing experienced operators (96.3%) to new operators (93.2%; $P = .256$).¹⁶ Similarly, there were no significant differences in complication rates between experienced and new operators.

A number of different devices were represented among the observational studies; however, the Watchman and PLAATO devices were the most frequently studied. In these studies, the device was successfully deployed in most patients selected to undergo the procedure, regardless of the device used. In one study, device deployment rates were similar in the Watchman device (98.8%, 165 of 167) and the Amplatzer Cardiac Plug (ACP) device (90%, 9 of 10).²² Rates of device closure as determined by follow-up TEE were high among studies of different devices reporting this outcome, but there was substantial variation in the timing of follow-up, and a substantial proportion of patients did not undergo follow-up TEE.

Table 3. Health outcomes, adverse effects, and procedural success in trials comparing percutaneous LAAO to warfarin therapy

Study, Setting, Mean follow-up time	Patient characteristics, T vs C	KQ1. Health outcome effects, T vs C	KQ2. Harms associated with LAA exclusion, T vs C	KQ4. Rates of procedural success, T vs C
PREVAIL ¹⁶ 50 sites, USA 11.8 months	N patients: 269 vs 138 Mean age: 74.0 vs 74.9 Male %: 67.7 vs 74.6 CHADS2 mean: 2.6 vs 2.6 CHA2DS2-VASc mean: 3.8 vs 3.9 AF %: 100 vs 100 Stroke %: 27.5 vs 28.3 CHF %: 23.4 vs 23.2 HTN %: 88.5 vs 97.1 (<i>P</i> = .003) DM %: 33.8 vs 29.7	Ischemic stroke: 5 of 269 (1.9%) vs 1 of 138 (0.7%) Hemorrhagic stroke: 1 of 269 (0.4%) vs 0 of 138 (0.0%) Death (cardiovascular/unexplained): 7 of 269 (2.6%) vs 3 of 138 (2.2%) Systemic embolism: 1 of 269 (0.4%) vs 0 of 138 (0.0%)	Total serious AEs: 11 (4.1%) of 269** Device embolization: 2 of 269 (0.7%) Arteriovenous fistula: 1 of 269 (0.4%) Cardiac perforation: 1 of 269 (0.4%) Pericardial effusion requiring surgery: 1 of 269 (0.4%) Pericardial effusion with pericardiocentesis: 4 of 269 (1.5%) Major bleed requiring transfusion: 1 of 269 (0.4%) Procedure-related stroke: 1 of 269 (0.4%)	252 (95.1%) successfully implanted of 265 attempted. Discontinuation of warfarin*, among N assessed by TEE: 227 (92.2%) of 246 at 45 days 235 (98.3%) of 239 at 6 months 141 (99.3%) of 142 at 12 months
PROTECT AF ¹²⁻¹⁴ 59 sites USA, Europe 12 months	N patients: 463 vs 244 Mean age: 71.7 vs 72.9 Male %: 70.4 vs 70.1 Mean CHADS: 2.2 vs 2.4 (<i>P</i> = .0517) AF %: 100 vs 100 Stroke/TIA %: 17.7 vs 20.1 CAD %: 39.6 vs 49.5 (<i>P</i> = .0275) CHF %: 26.8 vs 27.0 HTN %: 90.9 vs 90.3 DM %: 24.9 vs 30.6	Ischemic stroke: 15 of 463 (3.0%) vs 6 of 244 (2.5%) Cardiovascular/unexplained death: 5 of 463 (1.1%) vs 10 of 244 (4.1%), <i>P</i> <.05 Hemorrhagic stroke: 1 of 463 (0.2%) vs 6 of 244 (2.5%) Systemic embolism: 2 of 463 (0.4%) vs 0 of 244 (0%) All strokes: 16 of 463 (3.4%) vs 12 of 244 (4.9%) All-cause mortality: 21 of 463 (4.5%) vs 18 of 244 (7.4%) Quality of Life (QoL) assessed by Short-Form 12 vs 2, Mean change from baseline to 12 months: Total physical score: +0.4 vs -0.2, <i>P</i> = .0015 Total mental score: 0.0 vs -0.9, <i>P</i> = .6400 Physical functioning: +0.1 vs -3.0, <i>P</i> = .0005 Physical role limitation: +0.4 vs -2.35, <i>P</i> = .0021 Pain: -0.1 vs -1.0, <i>P</i> = .5668 General health: +0.8 vs -0.2, <i>P</i> = .0606 Vitality: +0.2 vs -1.4, <i>P</i> = .1614 Social functioning: +0.5 vs -1.6, <i>P</i> = .0650 Emotional role limitation: -0.3 vs -1.8, <i>P</i> = .1115 Mental health: 0.0 vs -0.9, <i>P</i> = .6780	Total serious AEs: 49 (10.5%) of 463 vs 20 (8.2%) of 244 Pericardial effusion requiring surgery: 15 of 463 (3.2%) Pericardial effusion with pericardiocentesis: 7 of 463 (1.5%) Device embolization: 3 of 463 (0.6%) Major bleeding: 16 of 463 (3.4%) Procedure-related stroke: 6 of 463 (1.1%) Other: 2 of 463 (0.4%) 27 (55%) of 49 primary safety events occurred on the day of the procedure. Timing of specific AEs not otherwise stated.	408 (91%) successfully implanted of 449 attempted. Discontinuation of warfarin*, among N assessed by TEE: At 45 days: 348 (86%) of 401. 30 (7.5%) of 401 continued warfarin due to continued shunt At 6 months: 355 (92%) of 385. 14 (3.6%) of 385 continued warfarin due to continued shunt Control arm was within therapeutic INR range 66% of the time.

*Implies complete closure or residual peri-device flow <5mm in width on TEE.

**Total serious AEs in our report differs from primary source as we included procedure related strokes and pericardial effusions requiring any intervention.



Table 4. Procedural success, harms, and long-term stroke risk in registry studies of percutaneous LAA exclusion

Study, Setting	Device; Mean follow-up; N patients; Eligible/ineligible for LT-OAC	Patient characteristics	Periprocedural harms occurring within 7 days	Longer-term harms	Procedural success: Deployment, N (%) of attempted Closure, N (%) of patients assessed by TEE
Bartus, 2013 ¹⁷ Poland	Lariat 1 year N=89 Ineligible for LT-OAC	Mean age: 62 Male %: 57 CHADS2 mean: 1.9 CHA2DS2-VASc mean: 2.8 HAS-BLED mean: 2.4 Stroke/TIA %: 25 CAD %: 4 CHF %: 12 HTN %: 94 DM %: 10	Serious procedure- or device-related safety events: Pericarditis: 2 (2.4%) of 85	Pericardial effusion: 1 (1.2%) of 85 At 3 months, sudden cardiac death: 1 (1.2%) of 85 At 6 months, hemorrhagic stroke: 1 (1.2%) of 85 At 1 year, lacunar stroke: 1 (1.2%) of 85	Deployment: 85 (95.5%) of 89 Closure: 1 day: 81 (95%) of 85 30 days: 81 (95%) of 85 90 days: 77 (95%) of 81 1 year: 64 (98%) of 65
Price, 2014 ²³ 8 sites USA	Lariat 112 days, median N=154 No criteria for LT-OAC; 60% were using an OAC at baseline	Mean age: 72 Male %: 62 CHADS 2 mean: 2.8 Cha2DS2-VASc mean: 4.1 HAS-BLED mean: 3.2 CHF %: 34 Stroke/TIA %: 38 HTN %: 81 DM %: 36	Serious procedure- or device-related safety events occurred in 21 (13.6%) of 154 Major bleed: 14 (9.1%) of 154 Cardiac tamponade: 7 (4.5%) of 154	Thrombus formation: 4 (3%) of 134 with follow-up available	Deployment: 145 (94.2%) of 154 Closure at end of procedure: 133 (92%) of 145 Closure at follow-up: 50 (79%) of 63
Nietlispach, 2013 ¹⁸ Single center Switzerland	Nondedicated LAA occlusion devices (off-label use of Amplatzer PFO, ASD and VSD occluders), N=32 Amplatzer ACP, N=120 32 months Eligible for LT-OAC	Mean age 72 Male %: 69 Mean CHA2DS2-Vasc: 3.46 Mean HASBLED score: 2.46 Stroke %: 31 HTN %: 75 DM %: 23	Serious procedure- or device-related safety events: 19 (12.5%) of 152 Cardiac tamponade: 4 (2.6%) of 152 Device embolizations: 6 (4.0%) of 152 Device dislocations: 3 (1.7%) of 179 Pericardial effusion: 2 (1.1%) of 179 Neurologic events (2 TIA and 1 minor stroke): 3 (2.0%) of 152 GI bleeding resulting in death: 1 (0.7%) of 152	Embolization: 1 (0.7%) of 152 Bleeding: 13 (8.6%) of 152 4 were major bleeds (2.6%): 2 intracerebral bleeds 2 subdural hematoma Ischemic stroke: 1 (0.7%)	Deployment: 146 (96.0%) of 152 Closure at 3-6 months: 137 (93.8%) of 146

Study, Setting	Device; Mean follow-up; N patients; Eligible/ineligible for LT-OAC	Patient characteristics	Periprocedural harms occurring within 7 days	Longer-term harms	Procedural success: Deployment, N (%) of attempted Closure, N (%) of patients assessed by TEE
Bayard, 2010 ²⁸ 18 centers Europe	PLAATO N=180 9.6 months Ineligible for LT-OAC	Mean age: 70 Male %: 66 Mean CHADS2 score: 3.1 CHF %: 42 Stroke/TIA %: 59 HTN %: 83 DM %: 29	Serious procedure- or device-related safety events: 8 (4.9%) of 162 Cardiac tamponade: 6 (3.7%) of 162 Cardiac death, procedure related: 2 (1.2%) of 162	Stroke (at 129 patient-years follow-up): 2.3% Cardiac death: 5 (3.1%) of 162	Deployment: 162 (90%) of 180 Closure at 2 months: 126 (90%) of 140
Block, 2009 ²⁰ USA	PLAATO 5 years N=64 Ineligible for LT-OAC	Mean age: 73 Male %: 60.9 CHADS2 score of 1, %: 23.4 CHADS2 score 2+, %: 76.6 CHF %: 44 Stroke/TIA %: 69 HTN %: 77 DM %: 23.4	Serious procedure- or device-related safety events: 1 (1.6%) of 64 (cardiac tamponade requiring surgery)	Stroke: 8 of 64 (12.5%)	Deployment: 61 (95.3%) of 64 Closure immediately after procedure: 55 (98.2%) of 56 Closure at 1 month: 22 (100%) of 22
Park, 2009 ¹⁹ Single-center prospective registry, Germany	PLAATO 2 years N=73 Ineligible for LT-OAC	Age 72.7 Male %: 50.7 CHADS2 mean score: 2.52 Stroke: 34.2 CAD %: 53.4 HTN%: 94.4 DM %: 36.1	Serious procedure- or device-related safety events: 4 (5.5%) of 73 Pericardial effusion: 1 (1.4%) of 73 Device embolization resulting in sudden cardiac death 1 (1.4%) of 73 Stroke: 1 (1.4%) of 73 Device instability, explanted by open-heart surgery to avoid device embolization: 1 (1.4%) of 73	Stroke: 0 (0.0%)	Deployment: 71 (97.2%) of 73 Closure at 3-6 months: 52 (100%) of 52 18 patients refused follow-up TEE
Ostermayer, 2005 ²⁴ Multisite: USA, Europe, Canada	PLAATO 9.8 months N=111 Ineligible for LT-OAC	Age >= 65 yrs: 84% Age >75 yrs: 35% Male %: NR Mean CHADS2: 2.5 Stroke/TIA: 38% CAD: 41% CHF or LVEF <40%: 39% HTN: 72%	Serious procedure- or device-related safety events occurred in 7 (6.3%) of 111 Respiratory failure: 1 (0.9%) of 111 Pericardial effusion: 2 (1.8%) of 111; only 1 required pericardiocentesis Cardiac Tamponade: 2 (1.8%) of 111; both had pericardiocentesis Hemothorax: 1 (0.9%) of 111	Stroke: 2 of 111 (1.8%)	Deployment: 108 (97.3%) of 111 Closure at end of procedure: 86 (97.7%) of 88 1 month: 60 (100%) of 60 6 months: 49 (98.0%) of 50

Study, Setting	Device; Mean follow-up; N patients; Eligible/ineligible for LT-OAC	Patient characteristics	Periprocedural harms occurring within 7 days	Longer-term harms	Procedural success: Deployment, N (%) of attempted Closure, N (%) of patients assessed by TEE
Reddy, 2013 ²⁵ Multisite Germany, Czech Republic, New York	Watchman 14.4 months N=150 Ineligible for LT-OAC	Age 72.5 Male %: 64 Mean CHADS2 score: 2.8 Mean CHAD2DS2-VASC score: 4.4 Stroke/TIA %: 40.7 CHF/reduced LVEF %: 28.7 Vascular disease %: 18 HTN %: 94.7 DM %: 32	Serious procedure- or device-related safety events occurred in 13 (8.7%) of 150 Pericardial effusion (with/without tamponade): 5 (3.3%) of 150 Device embolization: 2 (1.3%) of 150 Device thrombus: 6 (1.0%) of 150	Device thrombus with ischemic stroke, 341 days post-implant: 1 (0.7%) of 150 All-cause stroke or systemic embolism: 4 (2.7%) of 150 Ischemic stroke: 3 (2.0%) of 150 Hemorrhagic stroke: 1 (0.7%) of 150	Deployment: 142 (94.7%) of 150 Closure NR
CAP Registry ^{26,27} 26 centers	Watchman 16 months N=566 Eligible for LT-OAC	Mean age: 74 Male %: 65.5 CHADS mean: 2.4 CHADS score 1 = 25% CHADS score 2+ = 76% Stroke/TIA; 30.6% CHF %: 18.9 HTN %: 88.3 DM %: 24.7	Serious procedure/device-related safety AE: 17 (3.7%) of 460 Serious pericardial effusion: 10 of 460 (2.2%) Bleeding: 3 of 460 (0.7%) Respiratory failure: 2 of 460 (0.4%)	NR	Deployment: 437 (95.0%) of 460 Closure NR
Gafoor, 2014 ²¹ Single center Retrospective case review, single center Germany	Watchman, n=26 ACP, n=27 PLAATO, n=13 Lariat, n=4 Coherex, n=4 1 year Ineligible for LT-OAC	Mean age: 83.4 Male %: 53.3 Mean CHADS2 = 3.3 Mean CHA2DS-VASc = 5.2 Stroke %: 21.3 CAD %: 41.3 CHF %: 36 HTN %: 96 DM %: 22.7	Serious procedure- or device-related safety events occurred in 3 of 74 (4.1%) TIA: 1 of 74 (1.3%) Femoral bleeding (access site): 1 of 74 (1.3%) Device thrombus (patient not on anticoagulation): 1 of 74 (1.3%)	Death due to renal failure: 1 (1.4%) of 74 Stroke: 1 (1.4%) of 74	Deployment: 75 (100%) of 75 Closure at: 1 day: 68 (90.1% of 75 1 year: 97.4%, N with TEE not reported

Study, Setting	Device; Mean follow-up; N patients; Eligible/ineligible for LT-OAC	Patient characteristics	Periprocedural harms occurring within 7 days	Longer-term harms	Procedural success: Deployment, N (%) of attempted Closure, N (%) of patients assessed by TEE
Matsuo, 2014 ²² Single center Germany	Watchman® or Amplatzer Cardiac Plug (ACP®) device) 6 months N=179 Ineligible for LT-OAC	Mean age 72.7 Male %: 58.7 Mean CHADS2 score = 2.9 Mean CHA2DS2VASC = 4.3 Mean HASBLED = 3.9 Prior stroke/TIA %: 27.9 CHF %: 39.1 Vascular disease %: 24.0 HTN %: 95.0 DM %: 44.7	Serious procedure- or device-related safety events: 13 (7.3%) of 179 Cardiac tamponade: 2 (1.1%) Device dislocations: 3 (1.7%) Pericardial effusion: 2 (1.1%) Air embolization: 3 (1.7%) Device thrombus: 3 (1.7%)	Thrombus: 7 (4.2%) of 165 Among 145 with follow-up data at 6-months: Bleeding complications: 3 (2.0%) Upper GI bleeding: 2 (1.4%) Subdural hematoma: 1 (0.7%) Stroke: 0 (0.0%)	Deployment: Watchman: 163 (98.8%) of 165 ACP: 9 (90.0%) of 10 Closure at 45 days: 164 (99.4%) of 165 Discontinuation of OAC or Enoxaparine: 156 (94.5%) of 165

Abbreviations are found on page 5.

SURGICAL LAA INTERVENTIONS

KQ1: What is the effectiveness of LAA exclusion interventions compared with usual care?

Three randomized controlled trials and 2 observational studies evaluated the effectiveness of surgical LAA exclusion compared with usual care (Table 5).

In one trial of 43 patients undergoing open mitral valve surgery randomized to either LAA exclusion or control,²⁹ no postoperative death or stroke occurred in either group. The composite outcome of death, stroke or transient ischemic attack (TIA), and myocardial infarction (MI) in the postoperative period was also not significantly different (9.1% vs 4.5%, $P = 1.00$).

The LAAOS trial randomized 77 patients at risk for stroke undergoing elective coronary artery bypass grafting (CABG) without concomitant valve surgery to either LAA exclusion or control.³⁰ Two patients in the LAA exclusion group had perioperative stroke or TIA (2.6% vs 0%, P -value not reported). After being followed for an average of 13 +/- 7 months, no additional patients had stroke.

The LAAOS II trial randomized 51 patients with AF and increased stroke risk undergoing cardiac surgery using cardiopulmonary bypass to LAA exclusion or no occlusion with oral anticoagulation.³¹ At one year of follow-up there was no significant difference in the primary composite efficacy outcome of rate of death, MI, stroke, non-CNS embolism, and major bleeding (RR 0.7, 95% CI 0.2 to 2.7).

The 3 randomized controlled trials were found to have a low risk of bias. However, all were small pilot studies conducted to assess the safety and feasibility of larger trials and therefore were not powered and did not have adequate follow-up to detect clinically significant outcomes.

The 2 observational studies used propensity score matching to create comparator groups. One study reviewed 119 pairs of patients who underwent surgical ablation of AF over a mean follow-up of 3.1 +/- 2.8 years and found no significant differences in stroke-free survival ($P = .88$) and freedom from AF while off antiarrhythmic drugs ($P = .46$) between the 2 groups.³²

The other study reviewed 631 pairs of patients who had undergone a variety of cardiac surgical procedures and found that while the rate of postoperative atrial fibrillation was higher in the LAA exclusion group (23% vs 18%, $P = .037$), fewer of these patients had stroke through postoperative day 30 (0.0% vs 6.1%, $P = .003$).³³ However, there were more strokes in the LAA ligation group among patients without postoperative atrial fibrillation, so the overall rate of cerebrovascular accident (CVA) was not significantly different between the 2 groups ($P = .44$). All patients in this study underwent surgery by the same cardiothoracic surgeon, whose practices changed over the course of 10 years from performing no LAA exclusion to routine LAA exclusion during cardiac surgery. Other concurrent changes over time, such as changes in anticoagulation strategy in patients developing AF, may confound the findings of this study.

KQ2: What are the harms associated with LAA exclusion?

The same 3 randomized controlled trials and 2 observational studies evaluated the harms of surgical LAA exclusion (Tables 5 and 6).

One RCT found a trend towards longer median mechanical ventilation time in the LAA exclusion group (11.5 h vs 8 h, $P = .078$).²⁹ There was no significant difference in the composite of 10 major complications (death, cerebrovascular events, MI, respiratory failure, intra-aortic balloon pump, renal dysfunction, permanent pacemaker, septicemia, mediastinitis, and re-operation for bleeding) between the exclusion and control groups (32% vs 38%, $P = .75$).

The LAAOS trial found more intraoperative tears involving the left atrial appendage or the left atrium in the LAA exclusion group than the control group (15% vs 4%, P -value not reported).³⁰ However, performance of LAA occlusion did not significantly prolong cardiopulmonary bypass time ($P = .63$) and did not increase perioperative bleeding ($P = .53$), the occurrence of postoperative AF ($P = .56$), or diuretic use ($P = .87$).

The LAAOS II trial found no significant difference between the LAA exclusion and control groups for rates major bleeding (RR 0.4, 95% CI 0.0 to 4.6) or reoperation for bleeding (RR 1.9, 95% CI 0.2 to 19.9) and neither of the 2 reoperations in the LAA occlusion group was deemed secondary to bleeding at the LAA occlusion site.³¹ No significant difference was found for the total bypass time or cross-clamp time between the 2 groups.

Only one observational study reported harms associated with LAA exclusion and found no significant difference in early operative complications including reoperation due to bleeding (10.9% vs 5.0%, $P = .17$), requirement for dialysis (7.6% vs 8.4%, $P > 0.99$), permanent pacemaker insertion (3.4% vs 1.7%, $P = .63$), mediastinitis (0% vs 0.8%, $P > 0.99$), wound revision (0.8% vs 1.7%, $P > 0.99$) or pericardial effusion (6.7% vs 5.0%, $P = .77$).³²

KQ3: How do the benefits and harms of LAA exclusion vary in different subgroups?

We identified no trials evaluating subgroup differences in the benefits and harms of surgical LAA exclusion.

KQ4: What are the comparative effects of different techniques on health outcomes and rates of procedural success?

Two observational studies reported the comparative effects of different surgical techniques for LAA exclusion.

One study evaluated success of surgical LAA closure as determined by postoperative TEE after a mean time of 8.1 +/- 12 months.³⁴ Of 137 patients who underwent surgical excision, only 40% of all closures were successful. Successful LAA exclusion was found to be more common with excision (73%, $P < .001$) than suture exclusion (23%, $P > .001$) or stapler exclusion (0%, $P = .002$).

Another study compared anterior thoracotomy to video-assisted thoracoscopy (VATS) for LAA exclusion in 58 patients with chronic nonrheumatic AF. While there was no significant

difference between the groups for hospital stay (11.3 vs 9.1 days, $P = .61$) or duration of chest tube (4.3 vs 3.7 days, $P = .11$), there was a significant increase in operative time (77.3 vs 121.3 min, $P > .001$) in the VATS group.³⁵

Table 5. Characteristics and findings of trials of cardiac surgery with vs without concomitant LAA occlusion or removal

Study, Setting, Surgery performed	Technique; length of follow-up	Sample size and patient characteristics, T vs C	KQ1. Health outcome effects, T vs C	KQ2. Harms associated with LAA exclusion, T vs C	KQ4. Rates of procedural success, T vs C
Healey, 2005 ³⁰ Single site, Canada CABG	Sutures or stapler Mean 13 +/- 7 months	N: 52 vs 25 Age, mean: 72 vs 71 Male %: 73 vs 72 History of AF %: 17 vs 8 Stroke %: 17 vs 0 HTN %: 75 vs 92 DM %: NR	Mortality: 0 vs 0 Postoperative AF: 12/52 vs 4/25 Intraoperative ischemic stroke: 1/52 vs 0/25 TIA: 1/52 vs 0/25	Total serious AEs: 10 (19.2%) of 52 vs 1 (4%) of 25 Cross-clamp time (min): 72 vs 75 Intraoperative LAA tears: 8/52 vs 1/25 LAA tears in Tx group: Stapler: 4 Forceps: 2 Suture: 1 Not specified: 1 Perioperative stroke/TIA: 2 (2.6%) vs 0	TEE at 8 weeks postop: 29/44 (66%) with occlusion defined as no flow beyond the line of occlusion and a residual stump of <1 cm. 8 patients refused follow-up TEE. % with complete occlusion at 8 weeks, suture vs stapler (<i>P</i> = .14): 5/11 (45%) vs 24/33 (72%) Complete occlusion, stapling device vs sutures alone (<i>P</i> = .14.): 24 (72%) of 33 vs 5 (45%) of 11
Nagpal, 2009 ²⁹ Single center Italy Mitral valve surgery	Suture Postop period	N: 22 vs 21 Age, mean: 57.8 vs 59.2 Male %: 50 vs 57.1 AF %: 18.2 vs 19 TIA/stroke %: 0 vs 4.8 CAD %: 0 vs 0 DM %: 4.5 vs 0	Mortality: 0/22 vs 0/21 Stroke: 0/22 vs 0/21 TIA: 1/22 vs 1/21 MI: 1/22 vs 0/21	Total serious AEs: 7 (32%) of 22 vs 8 (38%) of 21 (<i>P</i> = .75) Mechanical ventilation time: 11.5 h vs 8 h (<i>P</i> = .078) Mean days in ICU: 2 vs 1 (<i>P</i> = .56) Composite of AEs (respiratory failure, IABP, renal dysfunction, PPM, sepsis, mediastinitis, re-op for bleeding): 5/22 vs 7/21	NR
Whitlock, 2013 ³¹ 4 sites, Canada CABG and/or valve replacement	Sutures or stapler 30 days (in person); 1 year (telephone)	N: 26 vs 25 Age, mean: 77.4 v 74.6 Male %: 76.92 vs 76 AF %: 100 vs 100 CVA %: 23 vs 20 TIA %: 12 vs 24 CAD %: 81 vs 84 CHF %: 27 vs 40 Valvular heart disease %: 81 vs 48* HTN %: 92 vs 92 DM %: 27 vs 28	Mortality: 2/26 vs 3/25 RR (95% CI): 0.64 (0.12 to 3.52) Stroke: 1/26 vs 3/25 RR (95% CI): 0.32 (0.03 to 2.88)	Total serious AEs: 4 (15.4%) of 26 vs 5 (20.0%) of 25 Major GI bleeding: 1/26 vs 2/25 Re-op for bleeding: 2/26 vs 1/25	NR

*"Baseline characteristics were well-balanced between the groups, with the exception that there was more valvular disease (*P* = .01) and a trend toward more valve surgery (*P* = .06) in the occlusion arm"³¹



Table 6. Characteristics and findings of cohort studies of cardiac surgery with vs without concomitant LAA occlusion or removal

Study, Setting, Surgery performed	Technique; length of follow-up	Sample size and patient characteristics, T vs C	KQ1. Health outcome effects, T vs C	KQ2. Harms associated with LAA exclusion, T vs C	KQ4. Rates of procedural success, T vs C
Kanderian, 2008 ³⁴ U.S.A. Valve surgery: 62% CABG + valve surgery: 31% Maze surgery: 39%	Excision (via scissors or an amputating stapling device) vs Exclusion (via suture or stapler exclusion with the LAA remaining attached). Mean time to TEE was 8.1 +/- 12 months	N: 52 excision vs 73 suture exclusion vs 12 stapler exclusion: Age: 64 vs 67 vs 37 Male %: 67 vs 48 vs 75 AF %: 54 vs 30 vs 8 HTN %: 58 vs 70 vs 50 Stroke %: 17 vs 14 vs 8 CHF %: 54 vs 73 vs 25 DM %: NR Warfarin use %: 69 vs 51 vs 33 Valve surgery %: 62 vs 59 vs 75 CABG + Valve surgery %: 20 vs 41 vs 25 Maze surgery %: 67 vs 22 vs 25	Stroke/TIA: 18 (13.1%) of 137: 6 with LAA excision 11 with suture exclusion, and 1 with stapler exclusion, (<i>P</i> = NS). Stroke/TIA among patients with successful vs unsuccessful LAA closure: 6 (11%) vs 12 (15%) (<i>P</i> = .61)	---	Excision: 38/52 (73%), <i>P</i> > .001 Suture exclusion: 17/73 (23%), <i>P</i> > .001 Stapler exclusion: 0/12, <i>P</i> = .002 Total: 55/137 (40%)
Kim, 2013 ³³ U.S.A. CABG %: 82.1 Valve surgery: 8.8% Combined CABG + valve surgery % = 8.6	LAA techniques varied over time: ligation; excision and oversewn; stapled. Retrospective chart review spanning 10 years.	N: 631 vs 631 CHADS2 score: 2.25 vs 2.29 Age: 66.2 vs 65.7 After propensity score matching: Male %: 68 vs 68 Hx stroke: 5 vs 5 CHF %: 81 vs 81 HTN %: 75 vs 75 DM %: 34 vs 34 PSM model included CA BG procedure, valve replacement, gender, age risk, Hx CHF, Hx HTN, Hx DM, and Hx CVA.	After propensity score matching: Postop AF %: 22.9 vs 18.2 (<i>P</i> = .037) Postop CVA %: 1.0 vs 1.4 (<i>P</i> = .44) Postop AF with CVA %: 0 vs 1.1 (<i>P</i> = .003) Among subjects with postop AF, N=145 vs 115: Postop CVA %: 0 vs 6% (<i>P</i> = .037)	---	---

Study, Setting, Surgery performed	Technique; length of follow-up	Sample size and patient characteristics, T vs C	KQ1. Health outcome effects, T vs C	KQ2. Harms associated with LAA exclusion, T vs C	KQ4. Rates of procedural success, T vs C
Lee, 2014 ³² Korea Mitral valve surgery with cryo-Maze procedure	Resection. Mean follow-up: 62.6 +/- 44.0 months. TEE at 1,3,6, and 12 months; ECG at 1,3,6,12,24, and 36 months.	N: 119 vs 119 After propensity matching: Age: 53.4 vs 54.1 Male %: 37.8 vs 41.2 HTN %: 18.5 vs 19.3 CHF %: 55.5 vs 53.8 DM %: 7.6 vs 7.6 Hx stroke: 5.0 vs 5.9 Hx cardiac surgery: 6.7 vs 4.2	Within 6 months: Mortality: 0/119 vs 1/119 Stroke: 1/119 vs 1/119 After 6 months: Mortality: 6/119 (5.0%) vs 10/119 (8.4%), RR (95% CI) 0.60 (0.22 to 1.60) Stroke/TIA 1/119 (0.8%) vs 2/119 (1.7%), RR (95% CI) 0.50 (0.05 to 5.44) AF: 11/119 vs 9/119	Total serious AEs: 35 (29.4%) of 119 vs 29 (24.4%) of 119 Reoperation due to bleeding: 13/119 vs 6/119 Requirement for dialysis: 9/119 vs 10/119 Permanent pacemaker insertion 4/119 vs 2/119 Mediastinitis: 0/119 vs 1/119 Wound revision: 1/119 vs 2/119 Pericardial effusion 8/119 vs 6/119	---
Muhammad, 2014 ³⁵ Saudi Arabia Anterior thoracotomy versus video-assisted thoracoscopy (VATS)	Anterior thoracotomy (open) vs VATS 2 years, by phone every 6 months	N: 29 (open) vs 29 (VATS) Age: 62 Male %: 60.3 HTN %: NR CHF %: NR DM %: NR	---	Total serious AEs: 2 (6.9%) of 29 vs 0 (0.0%) of 29	Open thoracotomy vs VATS: Operative time (min): 77.3 vs 121.3 (<i>P</i> < .001) Wound infection: 2/29 vs 0/29 Hospital stay, days: 11.3 vs 9.1 Duration of chest tube, days: 4.3 vs 3.7

SUMMARY AND DISCUSSION

Interest in mechanical exclusion of the LAA to reduce the risk of stroke in patients with atrial fibrillation has grown rapidly in recent years. We systematically reviewed the literature and found 12 studies assessing the benefits and harms of percutaneous approaches to LAA exclusion, and 7 studies assessing the benefits and harms of surgical LAA exclusion. Overall, there is limited evidence that one specific approach to percutaneous LAA exclusion may be an effective alternative to long-term oral anticoagulation in selected patients who are closely followed and in whom procedural success is sustained, though there are significant procedure-related harms. There is insufficient evidence to assess the benefits of surgical LAA exclusion, though these procedures do not appear to be associated with a significant increase in harms over the heart surgery during which the procedures are typically performed (Table 7).

Our findings corroborate and add to several recent systematic reviews,³⁶⁻³⁹ A recently published patient-level meta-analysis⁴⁰ similarly found no significant difference in risk of stroke between percutaneous LAA exclusion using the Watchman device and long-term warfarin therapy (HR 1.02, 95% CI 0.62 to 1.7).⁴⁰ In contrast to prior reviews we examined both percutaneous and surgical approaches to LAA exclusion. Also, we systematically examined both trial and observational study data.

Percutaneous LAA exclusion

There is low-strength evidence that percutaneous LAA exclusion with the Watchman device is associated with a similar risk of long-term stroke and mortality as continued oral anticoagulation therapy. Most patients who received the Watchman device were able to discontinue oral anticoagulant therapy after undergoing a follow-up TEE showing persistent closure of the LAA at 3-6 months. However, there is moderate-strength evidence that a substantial proportion of patients experienced serious periprocedural harms. There is insufficient evidence to determine whether factors such as operator experience, patient selection criteria, or choice of device can modify these risks.

There are several clinical situations in which percutaneous LAA exclusion may be a potentially attractive option, though the data directly supporting use in these circumstances is limited. First, LAA exclusion might be especially attractive for patients unable to take oral anticoagulants. However, the trial data most closely apply to patients who do not have contraindications to long-term oral anticoagulant therapy. In these trials, warfarin was used typically for 3-6 months until device endothelialization and LAA closure was achieved.

A number of observational studies included patients ineligible for long-term oral anticoagulant therapy,^{19-22,24,25} and while most found low rates of stroke over 1-2 years of follow-up, at least one study found higher incidence of stroke over a longer follow-up period.²⁰ Of note, even though warfarin was not used, patients in most of these studies used dual antiplatelet therapy for a duration ranging from 4 weeks to 6 months. Dual antiplatelet therapy (DAPT) in the population of patients with atrial fibrillation who have increased risk of stroke and for whom vitamin-K antagonists are unsuitable is associated with a 2.0% risk of major bleeding annually.⁴¹ It is notable that in a large study of warfarin versus DAPT for prevention of stroke in AF the risk of major bleeding was similar between groups (respectively 2.21% annual risk of stroke vs 2.42%,

RR 1.10, 95% CI 0.83-1.45, $P = .53$). Minor bleeding and overall bleeding was increased in patients taking DAPT compared to warfarin (15.4% risk per year vs 13.2%, RR 1.21, 95% CI 1.08-1.35, $P = .001$).⁴² Thus as long as the protocol for the use of LAA closure devices includes DAPT for any significant length of time it may not be an attractive option for patients who are high risk for bleeding complications and who do not wish to take, or have contraindications to, warfarin.

The clinical circumstances which contribute to anticoagulant ineligibility could also contribute to one's risk of suffering a periprocedural harm. While we do not have data to directly compare rates of periprocedural harms in patients eligible and ineligible for anticoagulant therapy, up to 8.7% of patients experienced a serious periprocedural safety event among 8 observational studies in patients ineligible for oral anticoagulant therapy.^{17,19-22,24,25,28}

The second clinical circumstance in which LAA exclusion might provide a useful alternative is for patients who might otherwise accrue a more substantial bleeding risk from oral anticoagulant therapy over longer time horizons. Take, for example, a 70 year-old woman with a history of atrial fibrillation, hypertension, and a prior stroke who is living independently and is a candidate for OAC. She has an annual stroke risk of 6.7% (based on CHADS₂-VASC = 5)¹ and would be expected to have a significant benefit from OAC. This same patient would be considered at high risk of major bleed (HAS-BLED = 3) with an expected 3.7 bleeds per 100 patient-years of follow-up while on OAC.⁴³ She will experience these annual risks of bleeding for the duration of her OAC therapy. In the PROTECT-AF trial, most events in the LAA exclusion group accrued earlier on in the study, while event rates in the control group increased steadily (though remained lower overall) over 3 years of follow-up.¹⁴ Theoretically, then, it is possible that the risks of long-term anticoagulation might eventually offset the near-term risks of LAA exclusion device placement. However, this has not been tested empirically and, given that not all cardioembolic strokes in atrial fibrillation originate in the left atrial appendage, it is certainly possible that long-term stroke risk in patients receiving a device who remain off anticoagulation may increase.

Third, some patients may simply prefer the placement of an LAA exclusion device over the inconvenience of long-term OAC. Policy makers will need to consider whether routine availability of periprocedural LAA exclusion for preference-sensitive indications is warranted.

There are a variety of devices being used for LAA exclusion, but there is not adequate evidence that the efficacy and safety of each of these devices is similar enough to comfortably extrapolate data from one device and apply to the use of a different device. While the techniques used for many of the devices are similar, there are still important differences, perhaps most notably for the Lariat device which takes an epicardial approach to snaring and externally excluding the LAA. For the time being, the evidence for device efficacy applies most closely to the Watchman device and there is insufficient evidence to determine the efficacy of other devices.

There is enough variation in the reported safety of percutaneous exclusion devices that, if the VHA does choose to pursue more widespread use of LAA exclusion procedures, an outcomes registry carefully tracking periprocedural and longer term harms should be established first, with results reviewed at periodic intervals. The finding that the multicenter observational studies often reported fairly high rates of serious periprocedural harms is troubling though the reasons for this

finding are not clear. It is possible that patient selection may be less restrictive and operator experience more variable with broader adoption of a procedure.

Finally, it should be noted that the decision to discontinue anticoagulant therapy in the included studies was based on demonstrated LAA closure on follow-up TEE. Up to 4-6% of patients had continued evidence of LAA blood flow at 6 months, and this may be an underestimate as these figures do not account for the proportion of patients in trials and observational studies who refused follow-up TEE. The benefits and harms of percutaneous LAA exclusion in patients for whom TEE monitoring is infeasible remain essentially unknown.

Surgical LAA exclusion

We found insufficient evidence to determine the efficacy of surgical LAA exclusion in reducing stroke. We found low strength evidence that surgical LAA exclusion in the context of heart surgery performed for another indication is unlikely to be associated with significant incremental harm.

While surgical LAA exclusion might seem analogous to performing an appendectomy during an exploratory laparotomy, the clinical implications may be quite different. The promise of surgical LAA exclusion is to reduce long-term risk of stroke and, possibly, to obviate the need for long-term oral anticoagulant therapy. However, we do not have sufficient evidence to determine whether prophylactic surgical LAA exclusion actually does reduce stroke. In the meantime, there is at least the theoretic possibility that surgical LAA exclusion may offer false reassurance to patients who then decide to discontinue oral anticoagulant therapy.

Limited data from one trial and one observational study suggest that a relatively high proportion of patients have persistent LAA blood flow detected on follow-up TEE.^{30,34} Given the lack of robust efficacy data, and the relatively low rates of long-term procedural success, patients who do undergo LAA exclusion during heart surgery should likely not discontinue long-term oral anticoagulant therapy.

Table 7. Summary of the evidence on percutaneous and surgical interventions to occlude or remove the LAA

Outcome	Device or procedure N studies (N=combined participants)	Findings	Strength of Evidence*	Comments
<i>Percutaneous interventions</i>				
Mortality	Watchman 2 RCTs (N=1,114)	No significant difference in mortality. RR (95% CI) in 2 RCTs: 1.20 (0.31 to 4.56) 0.62 (0.34 to 1.24)	Low	Limited applicability: only one device has been studied in 2 RCTs. Patients were eligible to receive LT-OAC.
Stroke	Watchman 2 RCTs (N=1,114)	No significant difference in risk of stroke. RR (95% CI): in 2 RCTs: 0.71 (0.35 to 1.64) 3.28 (0.37 to 25.31)		Low precision (wide confidence intervals).
Harms	ACP: 3 registries (N=147) Coherex: 1 registry (N=4) Lariat: 2 registries (N=93) PLAATO: 5 registries (N=441) Watchman: 2 RCTs + 4 registries (N=742) Device not specified: 2 registries (N=211)	Serious procedure- or device-related safety events (% of patients): 1.6 to 13.6 Overall, rate of serious adverse events within 7 days of device implantation was 6.5% (98/1506).	Moderate	Various devices were examined among 2 trials and 11 observational studies. Wide range of event rates across studies and relatively small number of patients treated in each observational study limited strength of findings.
<i>Surgical interventions</i>				
Mortality	Sutures or stapler in 3 RCTs (N=171) Various excision and exclusion techniques in 4 Cohort studies (N=1695)	No significant difference in mortality, among studies in which at least one event occurred in both groups: In 1 RCT: 7.7 vs 12% ($P > .05$) RR (95% CI) 0.64 (0.12, 3.52) In 1 cohort: 5.0 vs 8.4% ($P > .05$) RR (95% CI) 0.60 (0.22 to 1.60)	Insufficient	Trials too small and event rates too low to determine effectiveness of procedure.
Stroke	3 RCTs (N=171) 2 cohort studies (N=1500)	No significant difference in risk of stroke, among studies where at least one event occurred in both groups: In 1 RCT: 3.8 vs 12% ($P > .05$); RR (95% CI) 0.32 (0.03 to 2.88) In 2 cohorts: 1.0 vs 1.4% ($P = .44$) 0.84 vs 1.7% ($P > .05$)	Insufficient	
Harms	3 RCTs (N=171) 1 cohort study (N=238)	Serious safety events: 6.9-32.0% of patients No significant differences in most major harms between cardiac surgery groups with and without LAA exclusion	Low	Limited number of studies and limited number of patients included.

*The overall quality of evidence for each outcome is based on the consistency, coherence, and applicability of the body of evidence, as well as the internal validity of individual studies. The strength of evidence is classified as follows:¹¹

- High = Further research is very unlikely to change our confidence on the estimate of effect.
- Moderate = Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
- Low = Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
- Insufficient = Any estimate of effect is very uncertain.

LIMITATIONS

While we adhered to published standards for systematic review conduct, there are several potential methodologic limitations to note. First, we excluded non-English language studies. There is empiric data, however, suggesting that reviews restricted to English-language studies are largely concordant with reviews without language restrictions.⁴⁴ Second, we excluded observational studies enrolling fewer than 50 participants. However, we felt that these typically single-center studies with very small denominators were unlikely to yield reliable information about rates of harms or procedural success.

There are significant limitations in this body of evidence as a whole, and these are noted throughout our report. Clearly, one of the biggest limitations is simply the relative paucity of methodologically rigorous studies examining the efficacy of percutaneous and surgical LAA exclusion.

RESEARCH GAPS/FUTURE RESEARCH

Trials of percutaneous LAA interventions were limited to studies of the Watchman device in patients who were eligible for long-term warfarin therapy. Trials of surgical LAA interventions were few and limited by sample size. Several studies that should add substantively to this body of evidence are underway (Table 8), including a large RCT of surgical interventions with an estimated sample size of 4,700 patients; studies of recently developed percutaneous devices (Lambre and Occlutech); and a trial comparing Watchman with Apixaban in patients ineligible for warfarin therapy.

Table 8. Ongoing studies of percutaneous and surgical LAA interventions

Study title; Clinicaltrials.gov ID	Device or technique vs control	Study design; Estimated enrollment; Status; Estimated completion date	Country; Funding source	Comment
<i>Percutaneous interventions</i>				
Feasibility and Safety Study of LAMBRE Left Atrial Appendage Occluder; NCT01920412	Lambre	Single-group, open-label N=20 Recruiting as of Aug 2013; Est. completion: Sept 2014	China; Lifetech Scientific (Shenzhen) Co., Ltd.	First-in-man study
Safety and Efficacy Study of LAMBRE LAA Closure Device for Treating AF Patients Who Cannot Take Warfarin; NCT02029014	Lambre	Single group, open-label N=154 Recruiting as of Mar 2014; Est. completion: Jul 2016	China; Lifetech Scientific (Shenzhen) Co., Ltd.	Includes patients who cannot be treated long-term with Warfarin
Prospective, Non-randomized, Safety and Efficacy Study of a New Occluder Design for Minimally Invasive Closure of the Left Atrial Appendage (LAA) in Patients With Atrial Fibrillation (OLAAC); NCT02105584	Occlutech	Single group, open-label N=105 Recruiting as of Apr 2014; Est. completion: Apr 2016	Germany Occlutech International AB	Includes patients eligible or non-eligible for long-term oral anticoagulation therapy

Study title; Clinicaltrials.gov ID	Device or technique vs control	Study design; Estimated enrollment; Status; Estimated completion date	Country; Funding source	Comment
Left Atrial Appendage Closure vs Novel Anticoagulation Agents in Atrial Fibrillation (PRAGUE-17); NCT02426944	Watchman vs Apixaban	RCT, open-label N=400 Ongoing not recruiting as of April 2015; Est. completion: May 2020	Czech Republic; Charles University and Ministry of Health	Includes patients with significant bleeding during warfarin treatment
<i>Surgical interventions</i>				
Left Atrial Appendage Occlusion Study III (LAAOS III); NCT01561651	Cardiac surgery with vs without LAA occlusion via suture and/or surgical stapler	RCT, double-blinded N=4700 Recruiting as of May 2014; Est. completion: May 2019	Canada; Population Health Research Institute	Estimated mean follow-up of 4 years
Left Atrial Appendage CLOSURE for the Prevention of Thromboembolisms in Patients Undergoing Aortic Bioprosthesis Surgery (LAA-CLOSURE); NCT02321137	Valve surgery with vs without surgical LAA closure	RCT, open-label N=1040 Recruiting as of Dec 2014; Est. completion: Dec 2027	Finland and Netherlands; 5 regional/university hospitals	Includes patients with no indication for long-term anticoagulation

CONCLUSIONS

Overall, there is limited evidence that percutaneous LAA exclusion may be an effective alternative to long-term oral anticoagulation in selected patients who are closely followed and in whom procedural success is sustained. However, only one percutaneous device has been studied rigorously in trials, and percutaneous LAA exclusion has been associated with high rates of serious procedure-related harms in many studies. There is insufficient evidence to assess the benefits of surgical LAA exclusion. While surgical LAA exclusion does not appear to be associated with a significant increase in harms over the heart surgery during which the procedures are typically performed, rates of procedural success may be low. Overall, there is insufficient evidence to support the routine use of surgical LAA exclusion to reduce stroke risk or future need for anticoagulant therapy. There are a number of ongoing studies that should add substantively to this body of evidence over the next several years.

REFERENCES

1. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. *Circulation*. Dec 2 2014;130(23):2071-2104.
2. Arboix A, Alio J. Cardioembolic Stroke: Clinical Features, Specific Cardiac Disorders and Prognosis. *Curr Cardiol Rev*. Aug 2010;6(3):150-161.
3. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. *Ann Thorac Surg*. Feb 1996;61(2):755-759.
4. Manning WJ, Silverman DI, Gordon SP, Krumholz HM, Douglas PS. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. *The New England journal of medicine*. 1993;328(11):750-755.
5. Kansagara D, Noelck N, Papak J, et al. The effectiveness of procedures to remove or occlude the left atrial appendage. PROSPERO 2015:CRD42015016685 Available from http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015016685. Accessed July 28, 2015.
6. Sampson M, McGowan J, Lefebvre C, Moher D, Grimshaw J. *PRESS: Peer Review of Electronic Search Strategies*. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008.
7. Relevo R, Paynter R. *Peer review of search strategies*. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ Publication No. 12-EHC068-EF); 2012.
8. Chou R, Aronson N, Atkins D, et al. *Assessing Harms When Comparing Medical Interventions*. Rockville, MD Agency for Healthcare Research and Quality (AHRQ), Methods Reference Guide for Effectiveness and Comparative Effectiveness Reviews;2008.
9. Higgins JPT, Altman DG, editors. Chapter 8: Assessing risk of bias in included studies. In: *Cochrane Handbook for Systematic Reviews of Interventions*. 2008;Version 5.0.1. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org Accessed Dec 5, 2014.
10. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp Accessed July 30, 2015.
11. Berkman ND, Lohr KN, Ansari M, et al. Grading the Strength of a Body of Evidence When Assessing Health Care Interventions for the Effective Health Care Program of the Agency for Healthcare Research and Quality: An Update. Methods Guide for Comparative Effectiveness Reviews (Prepared by the RTI-UNC Evidence-based Practice Center under Contract No. 290-2007-10056-I). AHRQ Publication No. 13(14)-EHC130-EF. Rockville, MD: Agency for Healthcare Research and Quality. November 2013. <http://www.effectivehealthcare.ahrq.gov/ehc/products/457/1752/methods-guidance-grading-evidence-131118.pdf> Accessed on July 23, 2015

12. Alli O, Doshi S, Kar S, et al. Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) trial of patients at risk for stroke with nonvalvular atrial fibrillation. *J Am Coll Cardiol*. Apr 30 2013;61(17):1790-1798.
13. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.[Erratum appears in Lancet. 2009 Nov 7;374(9701):1596]. *Lancet*. Aug 15 2009;374(9689):534-542.
14. Reddy VY, Doshi SK, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. *Circulation*. Feb 12 2013;127(6):720-729.
15. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *Jama*. 2001;285(22):2864-2870.
16. Holmes DR, Jr., Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. *J Am Coll Cardiol*. Jul 8 2014;64(1):1-12.
17. Bartus K, Han FT, Bednarek J, et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. *J Am Coll Cardiol*. Jul 9 2013;62(2):108-118.
18. Nietlispach F, Gloekler S, Krause R, et al. Amplatzer left atrial appendage occlusion: single center 10-year experience. *Catheter Cardiovasc Interv*. Aug 1 2013;82(2):283-289.
19. Park J-W, Leithauser B, Gerk U, Vrsansky M, Jung F. Percutaneous left atrial appendage transcatheter occlusion (PLAATO) for stroke prevention in atrial fibrillation: 2-year outcomes. *J Invasive Cardiol*. Sep 2009;21(9):446-450.
20. Block PC, Burstein S, Casale PN, et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. *JACC Cardiovasc Interv*. Jul 2009;2(7):594-600.
21. Gafoor S, Franke J, Bertog S, et al. Left atrial appendage occlusion in octogenarians: short-term and 1-year follow-up. *Catheter Cardiovasc Interv*. Apr 1 2014;83(5):805-810.
22. Matsuo Y, Sandri M, Mangner N, et al. Interventional closure of the left atrial appendage for stroke prevention. *Circ J*. 2014;78(3):619-624.
23. Price MJ, Gibson DN, Yakubov SJ, et al. Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium. *J Am Coll Cardiol*. Aug 12 2014;64(6):565-572.
24. Ostermayer SH, Reisman M, Kramer PH, et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. *J Am Coll Cardiol*. Jul 5 2005;46(1):9-14.

25. Reddy VY, Mobius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). *J Am Coll Cardiol*. Jun 25 2013;61(25):2551-2556.
26. Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. *Circulation*. Feb 1 2011;123(4):417-424.
27. Gangireddy SR, Halperin JL, Fuster V, Reddy VY. Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit. *Eur Heart J*. Nov 2012;33(21):2700-2708.
28. Bayard Y-L, Omran H, Neuzil P, et al. PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study. *EuroIntervention*. Jun 2010;6(2):220-226.
29. Nagpal AD, Torracca L, Fumero A, Denti P, Cioni M, Alfieri O. Concurrent prophylactic left atrial appendage exclusion: results from a randomized controlled trial pilot study. *Eur J Cardiothorac Surg*. Sep 2009;36(3):553-557.
30. Healey JS, Crystal E, Lamy A, et al. Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. *Am Heart J*. Aug 2005;150(2):288-293.
31. Whitlock RP, Vincent J, Blackall MH, et al. Left Atrial Appendage Occlusion Study II (LAAOS II). *Can J Cardiol*. Nov 2013;29(11):1443-1447.
32. Lee C-H, Kim JB, Jung S-H, Choo SJ, Chung CH, Lee JW. Left atrial appendage resection versus preservation during the surgical ablation of atrial fibrillation. *Ann Thorac Surg*. Jan 2014;97(1):124-132.
33. Kim R, Baumgartner N, Clements J. Routine left atrial appendage ligation during cardiac surgery may prevent postoperative atrial fibrillation-related cerebrovascular accident. *J Thorac Cardiovasc Surg*. Feb 2013;145(2):582-589; discussion 589.
34. Kanderian AS, Gillinov AM, Pettersson GB, Blackstone E, Klein AL. Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography. *J Am Coll Cardiol*. Sep 9 2008;52(11):924-929.
35. Muhammad MIA. Role of video-assisted thoracoscopy in the management of stroke. *Asian Cardiovasc Thorac Ann*. Feb 2014;22(2):155-159.
36. Chatterjee S, Herrmann HC, Wilensky RL, et al. Safety and Procedural Success of Left Atrial Appendage Exclusion With the Lariat Device: A Systematic Review of Published Reports and Analytic Review of the FDA MAUDE Database. *JAMA internal medicine*. Jul 1 2015;175(7):1104-1109.
37. Bajaj NS, Parashar A, Agarwal S, et al. Percutaneous left atrial appendage occlusion for stroke prophylaxis in nonvalvular atrial fibrillation: a systematic review and analysis of observational studies. *JACC Cardiovasc Interv*. Mar 2014;7(3):296-304.

38. Munkholm-Larsen S, Cao C, Yan TD, Pehrson S, Dixen U. Percutaneous atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: a systematic review. *Heart*. Jun 2012;98(12):900-907.
39. Bode WD, Patel N, Gehi AK. Left atrial appendage occlusion for prevention of stroke in non-valvular atrial fibrillation: A meta-analysis. *Circulation*. 2014;130((Bode W.D.; Gehi A.K.) Dept of Medicine, Div of Cardiology, Univ of North Carolina at Chapel Hill, Chapel Hill, United States).
40. Holmes DR, Jr., Doshi SK, Kar S, et al. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. *J Am Coll Cardiol*. Jun 23 2015;65(24):2614-2623.
41. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. *N Engl J Med*. May 14 2009;360(20):2066-2078.
42. Active Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. *Lancet*. 2006;367(9526):1903-1912.
43. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest*. Nov 2010;138(5):1093-1100.
44. Moher D, Pham B, Lawson ML, Klassen TP. The inclusion of reports of randomised trials published in languages other than English in systematic reviews. *Health technology assessment (Winchester, England)*. 2003;7(41):1-90.
45. Viles-Gonzalez JF, Kar S, Douglas P, et al. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. *J Am Coll Cardiol*. Mar 6 2012;59(10):923-929.